Fly News Breaks for October 21, 2019
Oct 21, 2019 | 16:05 EDT
Goldman Sachs analyst Paul Choi said Seattle Genetics' (SGEN) positive top-line results from its HER2CLIMB trial of tucatinib in HER2+ breast cancer patients likely affirm a narrower metastatic opportunity for Puma Biotechnology's (PBYI) Nerlynx. Nerlynx will have a first-mover advantage, acknowledges Choi, but he continues to expect low market penetration based on its side effects and lack of an OS benefit, leading him to maintain a Sell rating on Puma shares.
News For PBYI;SGEN From the Last 2 Days
There are no results for your query PBYI;SGEN